# NovaXS Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novaxs-biotech

- Industry: Biotechnology
- Headquarters: US
- Website: www.novaxs.co
- Total disclosed funding: $1.5M
- Latest round: Seed (Mar 31, 2022)
- Investors on record: 5

## About

Based in California, US, and founded in 2021 by Alina Su, NovaXS Biotech Corp. operates as a therapeutic company. In March 2022, NovaXS Biotech Corp. raised USD 1.5 million in seed funding led by new investor NewGen Venture Partners, along with investors Baxter International, Inc., Courtyard Ventures, Edward-Elmhurst Healthcare, and mHUB.

NovaXS Biotech Corp. develops a drug delivery platform and provides CRISPR gene therapy nanoparticle delivery. The company provides an injection gun, which patients can hold in their hands and push biologics into the body’s subcutaneous and intramuscular level within 0.3 seconds using liquid pressure. The device also comes with a cloud-based platform that collects patient information for physicians, like injection time, frequency, dosage volume, and medication temperature.

The company plans to use the investment to work on the safety and stability of its products, apply for FDA clearance, and put together its core management team.

## Funding rounds

- Seed, Mar 31, 2022, $1.5M — Baxter International, Inc., NewGen Venture Partners, Edward-Elmhurst Healthcare, mHUB, Courtyard Ventures

## Investors

- Baxter International, Inc. — Seed
- NewGen Venture Partners (https://capitalatlas.ai/funds/newgen-venture-partners) — Seed
- Edward-Elmhurst Healthcare — Seed
- mHUB (https://capitalatlas.ai/funds/mhub) — Seed
- Courtyard Ventures (https://capitalatlas.ai/funds/courtyard-ventures) — Seed